甘草酸二铵联合胸腺素α1对病毒性肝炎患者血清胆碱酯酶、胆汁酸水平的影响  

Effect of Diammonium Glycyrrhizinate Combined with Thymosin α1 on Levels of Serum Cholinesterase and Total Bile Acids in Patients with Viral Hepatitis

作　　者：张国栋 ZHANG Guodong(General Hospital of Pingmei Shenma medical group,Pingdingshan 467000,Henan)

机构地区：[1]平煤神马医疗集团总医院,河南平顶山467000

出　　处：《新中医》2021年第16期96-100,共5页New Chinese Medicine

摘　　要：目的:观察甘草酸二铵联合胸腺素α1 (Tα1)对病毒性肝炎患者血清胆碱酯酶(CHE)、胆汁酸(TBA)水平的影响。方法:选取110例病毒性肝炎患者作为研究对象,按照分层抽样法分为对照组和联合组各55例。对照组采用Tα1治疗,联合组在对照组基础上加服甘草酸二铵治疗。分析2组治疗前后总胆固醇(TC)、甘油三酯(TG)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)、CD3+、CD4+、CD8+、白蛋白(Alb)、天冬氨酸转氨酶(AST)、丙氨酸转氨酶(ALT)、总胆红素(TBil)、TBA、Ⅲ型前胶原(PCⅢ)、Ⅳ型胶原(Ⅳ-C)、层粘连蛋白(LN)、CHE水平,并计算CD4+/CD8+。比较2组临床疗效及不良反应发生情况。结果:与同组治疗前比较,2组治疗后TC、TG、HDL-C、LDL-C、CD8+、AST、ALT、TBil、PCⅢ、Ⅳ-C、LN、TBA水平均降低(P<0.05),CD3+、CD4+、Alb、CHE水平及CD4+/CD8+均升高(P<0.05);与对照组治疗后比较,联合组治疗后TC、TG、HDL-C、LDL-C、CD8+、AST、ALT、TBil、PCⅢ、Ⅳ-C、LN、TBA水平均较低(P<0.05),CD3+、CD4+、Alb、CHE水平及CD4+/CD8+均较高(P<0.05)。联合组总有效率为98.18%,高于对照组的85.45%(P<0.05)。2组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:甘草酸二铵联合Tα1可有效缓解病毒性肝炎患者临床症状,提高CHE水平,降低TBA水平,改善肝功能,有一定的抗肝纤维化作用。Objective:To observe the effect of diammonium glycyrrhizinate combined with thymosin α1(Tα1) on levels of serum cholinesterase(CHE) and total bile acids(TBA) in patients with viral hepatitis. Methods:A total of 110 patients with viral hepatitis were selected and divided into the control group and the combination group according to stratified sampling method,55 cases in each group. The control group was treated with Tα1,and the combination group was additionally treated with diammonium glycyrrhizinate based on the treatment of the control group. The levels of total cholesterol(TC),triglyceride(TG),high density lipoprotein cholesterol(HDL-C),low density lipoprotein cholesterol(LDL-C),CD3+,CD4+,CD8+,albumin(Alb), aspartate aminotransferase(AST), alanine aminotransferase(ALT), total bilirubin(TBil), TBA, procollagen Ⅲ(PC Ⅲ),Type Ⅳ collagen(Ⅳ-C),laminin(LN) and CHE before and after treatment in the two groups were analyzed. The value of CD4+over CD8+was calculated. The clinical effect and the incidence of adverse reactions were compared between the two groups.Results:Compared with those before treatment,the levels of TC,TG,HDL-C,LDL-C,CD8+,AST,ALT,TBil,PCⅢ,Ⅳ-C,LN and TBA were all decreased in both groups after treatment(P<0.05);the levels of CD3+,CD4+,Alb,CHE and CD4+/CD8+were increased(P<0.05). the levels of TC,TG,HDL-C,LDL-C,CD8+,AST,ALT,TBil,PCⅢ,Ⅳ-C,LN and TBA in the combination group were lower than those in the control group(P<0.05),and the levels of CD3+,CD4+,Alb,CHE and CD4+/CD8+were higher(P<0.05). The total effective rate was 98.18% in the combination group,higher than that of85.45% in the control group(P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05). Conclusion: Diammonium glycyrrhizinate combined with Tα1 can effectively alleviate the clinical symptoms of patients with viral hepatitis,increase CHE level,reduce TBA level and improve liver function,which has a antiliver fibrosis effect.

关 键 词：病毒性肝炎 甘草酸二铵 胸腺素Α1 胆碱酯酶 胆汁酸 

分 类 号：R512.6[医药卫生—内科学]